<DOC>
	<DOCNO>NCT01164345</DOCNO>
	<brief_summary>The aim study evaluate Plerixafor ( MOZOBIL ) plus recombinant human G-CSF ( G-CSF ) efficiency mobilize sufficient number stem cell Lymphoma ( NHL HL ) patient autologous transplantation .</brief_summary>
	<brief_title>Mozobil Autologous Stem Cell Mobilization</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Patients eligible plan autologous haematopoietic stem cell transplantation . 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 1.2 WBC count ≥2.5x109/L . 1.3 Absolute neutrophil count ≥1.5x109/L . 1.4 Platelet count ≥100x109/L 1.5 Adequate cardiac , renal , hepatic pulmonary function sufficient undergo apheresis transplantation . 1.6 Previously , heavily pretreated lymphoma patient patient suspect poor bone marrow stem cell reserve least one following : &gt; 2 line chemotherapy . Previous radiotherapy involve bone marrow Prior therapy specific stem cell toxic chemotherapeutic agent Platelets count premobilisation , ≤150.103 x mm3 Level circulate CD34+ ≤ 20 cells/mcL prior apheresis collection day Patients &gt; 60 year age 2.1 Lymphoma patient fulfil inclusion criterion . 2.2 History acute chronic leukemia ( include myelodysplastic syndrome . 2.3 Prior allogeneic autologous transplantation . 2.4 Inability tolerate stem cell harvest . 2.5 Peripheral venous access possible . 2.6 Pregnant nursing woman . 2.7 Positive serology hepatitis B C. 2.8 Acute infection ( febrile , i.e . temperature &gt; 38C ) within 24 hour prior dose antibiotic therapy within 7 day prior first dose GCSF . 2.9 HIV positive . 2.10 Left ventricular ejection fraction &lt; 50 % . 2.11 DLCO &lt; 50 % . 2.12 Splenectomised splenic irradiation . 2.13 Psychiatric , addictive , disorder/disease compromise ability give inform consent participation study . 2.14 Treatment investigational drug within 4 week enrol protocol currently enrol another investigational protocol mobilisation phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>